In the race to produce the first NASH treatment, Gilead Sciences' most advanced candidate has failed the first of two Phase 3 trials. There were already low expectations around Intercept Pharmaceuticals's potential for treating NASH, or nonalcoholic steatohepatitis, for which there are currently no FDA-approved treatments. The spread of the condition is being driven by widespread obesity and can cause liver failure, requiring a transplant. Big pharmaceutical firms, including Gilead, have already spent hundreds of millions of dollars to acquire NASH candidates. Selonsertib and Genfit look best set to report their own Phase 3 data later this year.
In the race to produce the first NASH treatment, Gilead Sciences' most advanced candidate has failed the first of two Phase 3 trials. There were already low expectations around Selonsertib's potential for treating NASH, or nonalcoholic steatohepatitis, for which there are currently no FDA-approved treatments. The spread of the condition is being driven by widespread obesity and can cause liver failure, requiring a transplant. Big pharmaceutical firms, including Gilead, have already spent hundreds of millions of dollars to acquire NASH candidates. Intercept Pharmaceuticals and Genfit look best set to report their own Phase 3 data later this year.